PRKCE non-coding variants influence on transcription as well as translation of its gene.
Protein kinase C epsilon
Transcription
gene expression
transcription factors
untranslated region variations
Journal
RNA biology
ISSN: 1555-8584
Titre abrégé: RNA Biol
Pays: United States
ID NLM: 101235328
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
29
10
2022
Statut:
ppublish
Résumé
Untranslated regions of the gene play a crucial role in gene expression regulation at mRNA and protein levels. Mutations at UTRs impact expression by altering transcription factor binding, transcriptional/translational efficacy, miRNA-mediated gene regulation, mRNA secondary structure, ribosomal translocation, and stability. PKCε, a serine/threonine kinase, is aberrantly expressed in numerous diseases such as cardiovascular disorders, neurological disorders, and cancers; its probable cause is unknown. Therefore, in the current study, the influence of PRKCE 5'-and 3'UTR variants was explored for their potential impact on its transcription and translation through several bioinformatics approaches. UTR variants data was obtained through different databases and initially evaluated for their regulatory function. Variants with regulatory function were then studied for their effect on PRKCE binding with transcription factors (TF) and miRNAs, as well as their impact on mRNA secondary structure. Study outcomes indicated the regulatory function of 73 5'UTR and 17 3'UTR variants out of 376. 5'UTR variants introduced AP1 binding sites and promoted the PRKCE transcription. Four 3'UTR variants introduced a circular secondary structure, increasing PRKCE translational efficacy. A region in 5'UTR position 45,651,564 to 45,651,644 was found where variants readily influenced the miRNA-PRKCE mRNA binding. The study further highlighted a PKCε-regulated feedback loop mechanism that induces the activity of TFs, promoting its gene transcription. The study provides foundations for experimentation to understand these variants' role in diseases. These variants can also serve as the genetic markers for different diseases' diagnoses after validation at the cell and population levels.
Identifiants
pubmed: 36299231
doi: 10.1080/15476286.2022.2139110
pmc: PMC9621080
doi:
Substances chimiques
5' Untranslated Regions
0
3' Untranslated Regions
0
Genetic Markers
0
RNA, Messenger
0
MicroRNAs
0
Transcription Factors
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
Serine
452VLY9402
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115-1129Références
Mol Cell. 2008 May 23;30(4):460-71
pubmed: 18498749
Pharmacogenomics J. 2018 Jul;18(4):556-564
pubmed: 29282362
BMC Genomics. 2008 Jan 14;9:18
pubmed: 18194548
Endocrine. 2021 Dec;74(3):498-507
pubmed: 34599696
J Pathol. 2019 Apr;247(5):574-588
pubmed: 30584801
Front Endocrinol (Lausanne). 2018 Aug 21;9:471
pubmed: 30186235
Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a003665
pubmed: 20685845
Nature. 2021 Feb;590(7845):290-299
pubmed: 33568819
Nat Rev Genet. 2020 Aug;21(8):448
pubmed: 32488197
RNA. 2004 Oct;10(10):1507-17
pubmed: 15383676
Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8996-E9005
pubmed: 30181290
Cancer Res. 2020 Dec 1;80(23):5166-5173
pubmed: 32994205
Methods Mol Biol. 2010;628:307-19
pubmed: 20238089
EMBO J. 1994 Aug 15;13(16):3882-91
pubmed: 8070415
Curr Opin Genet Dev. 2022 Aug;75:101919
pubmed: 35609422
Methods Mol Biol. 2007;396:71-91
pubmed: 18025687
Sci Rep. 2019 Feb 14;9(1):2125
pubmed: 30765820
Mol Genet Genomic Med. 2022 Apr;10(4):e1892
pubmed: 35247231
BMC Bioinformatics. 2007 Nov 09;8:437
pubmed: 17996093
DNA Cell Biol. 2021 Feb;40(2):219-230
pubmed: 33332227
Mol Cancer. 2021 Jan 4;20(1):3
pubmed: 33397405
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Cold Spring Harb Perspect Biol. 2019 Oct 1;11(10):
pubmed: 30181377
Cell. 2017 Jan 26;168(3):344-361
pubmed: 28129536
J Alzheimers Dis. 2015;43(2):491-509
pubmed: 25125477
Int J Mol Sci. 2022 Oct 27;23(21):
pubmed: 36361806
BMC Med Genomics. 2012 Apr 30;5:11
pubmed: 22546513
Tumour Biol. 2015 Jul;36(7):5241-7
pubmed: 25663494
J Biol Chem. 2012 Oct 26;287(44):37570-82
pubmed: 22955280
Cell Mol Life Sci. 2019 Feb;76(3):441-451
pubmed: 30374521
J Biol Chem. 2020 Aug 14;295(33):11693-11706
pubmed: 32571876
Nucleic Acids Res. 2006;34(17):4925-36
pubmed: 16982645
Methods Mol Biol. 2017;1580:225-237
pubmed: 28439836
J Hum Genet. 2016 Oct;61(10):861-866
pubmed: 27305981
BMC Bioinformatics. 2008 Jun 09;9:271
pubmed: 18541026
Nucleic Acids Res. 2003 Jul 1;31(13):3429-31
pubmed: 12824340
Yale J Biol Med. 2016 Dec 23;89(4):513-525
pubmed: 28018142
Pharm Res. 2017 Aug;34(8):1648-1657
pubmed: 28120175
Nat Genet. 2007 Feb;39(2):212-7
pubmed: 17206144
J Immunol. 2000 Jul 1;165(1):271-9
pubmed: 10861061
Biochim Biophys Acta Proteins Proteom. 2021 Jun;1869(6):140621
pubmed: 33561576
Antioxidants (Basel). 2022 Apr 06;11(4):
pubmed: 35453404
Genome Res. 2012 Sep;22(9):1790-7
pubmed: 22955989
Proc Natl Acad Sci U S A. 2007 Jun 5;104(23):9667-72
pubmed: 17535905
Mol Carcinog. 2015 Aug;54(8):632-41
pubmed: 24510606
Wiley Interdiscip Rev RNA. 2018 Jul;9(4):e1474
pubmed: 29582564
Neuropathol Appl Neurobiol. 2022 Apr;48(3):e12775
pubmed: 34820881
Nat Commun. 2016 Apr 18;7:11321
pubmed: 27089238
Cancer Gene Ther. 2020 Nov;27(10-11):773-784
pubmed: 31831855
Nat Rev Mol Cell Biol. 2018 Mar;19(3):158-174
pubmed: 29165424
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
BMC Cancer. 2022 May 7;22(1):518
pubmed: 35525950
Nucleic Acids Res. 2021 Jan 8;49(D1):D10-D17
pubmed: 33095870
Nat Rev Genet. 2012 Sep;13(9):613-26
pubmed: 22868264
Hum Mol Genet. 2022 Jul 7;31(13):2236-2261
pubmed: 35137073
RNA. 2004 Aug;10(8):1178-90
pubmed: 15272118
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827
Mol Cell Biol. 2012 Aug;32(16):3281-92
pubmed: 22711990
Gene. 2018 Jun 5;658:70-75
pubmed: 29514046
Nat Commun. 2020 Oct 8;11(1):5079
pubmed: 33033234
Curr Cancer Drug Targets. 2016;16(9):765-772
pubmed: 26881929
Curr Protoc Bioinformatics. 2010 Dec;Chapter 1:Unit 1.19
pubmed: 21154707
Front Oncol. 2014 Mar 11;4:45
pubmed: 24653979
Int Immunopharmacol. 2022 Jul;108:108905
pubmed: 35729836
Nature. 2004 Nov 4;432(7013):112-8
pubmed: 15525991
Biomed Res Int. 2020 Dec 28;2020:1354381
pubmed: 33490232
Hum Genet. 2017 Sep;136(9):1093-1111
pubmed: 28497172
In Silico Biol. 2002;2(1):S1-15
pubmed: 11808873
Front Oncol. 2022 May 30;12:840046
pubmed: 35707351
Sci Rep. 2021 Aug 30;11(1):17343
pubmed: 34462460
Biosci Rep. 2020 Sep 30;40(9):
pubmed: 32869841
Am J Clin Pathol. 2012 Aug;138(2):230-5
pubmed: 22904134
Mol Cancer Res. 2018 Jan;16(1):3-15
pubmed: 29021232
Nat Rev Cancer. 2019 Jun;19(6):326-338
pubmed: 31053804
Cell Mol Life Sci. 2012 Nov;69(21):3613-34
pubmed: 22538991
BMC Neurosci. 2018 Nov 29;19(1):76
pubmed: 30497386
Sci Rep. 2022 May 16;12(1):8039
pubmed: 35577881
Database (Oxford). 2015 Apr 08;2015:bav035
pubmed: 25858286
Adv Biol Regul. 2020 Dec;78:100759
pubmed: 33039823
Oncotarget. 2016 Nov 22;7(47):78055-78068
pubmed: 27801665
Front Cardiovasc Med. 2022 Mar 21;9:841032
pubmed: 35387445
Clin Pharmacol Ther. 2014 Nov;96(5):609-15
pubmed: 25054431